Advertisement

Topics

[Articles] Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet—a population-based study

23:34 EDT 4 Jul 2017 | The Lancet

Our study benefits from the largest pool of population-based registries to estimate incidence and survival of about 200 rare cancers. Incidence trends can be explained by changes in known risk factors, improved diagnosis, and registration problems. Survival could be improved by early diagnosis, new treatments, and improved case management. The centralisation of treatment could be improved in the seven European countries we studied.

Original Article: [Articles] Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet—a population-based study

NEXT ARTICLE

More From BioPortfolio on "[Articles] Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet—a population-based study"

Advertisement
Quick Search
Advertisement
Advertisement